603939 益丰药房
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入17,218,8988.38%22,588,22719,886,39615,326,30513,144,502
减:营业总成本15,712,0098.57%20,616,59718,008,27514,045,64112,062,111
    其中:营业成本10,263,8376.86%13,957,59912,025,5649,142,8188,152,071
               财务费用122,43094.31%86,185104,812114,870141,522
               资产减值损失(59,754)11.78%(72,634)(56,019)(40,746)(31,404)
公允价值变动收益------------
投资收益76,803111.89%42,3726,86934,36829,420
    其中:对联营企业和合营企业的投资收益(1)-39.10%317(11)--2,168
营业利润1,585,5447.95%2,054,7851,885,5331,338,8671,133,484
利润总额1,579,9927.64%2,037,5941,877,4871,337,9061,127,365
减:所得税费用381,57412.38%456,663454,061347,157287,923
净利润1,198,4186.22%1,580,9311,423,426990,749839,443
减:非控股权益87,918-31.89%168,946161,585102,86495,920
股东净利润1,110,50111.14%1,411,9851,261,841887,884743,523

市场价值指针
每股收益 (元) *0.92010.84%1.4001.2601.2501.080
每股派息 (元) *0.250--0.5000.4000.3000.300
每股净资产 (元) *8.274-10.98%9.70211.85510.4099.883
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容